Correlation Between NextCure and Design Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both NextCure and Design Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NextCure and Design Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between NextCure and Design Therapeutics, you can compare the effects of market volatilities on NextCure and Design Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NextCure with a short position of Design Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of NextCure and Design Therapeutics.

Diversification Opportunities for NextCure and Design Therapeutics

-0.37
  Correlation Coefficient

Very good diversification

The 3 months correlation between NextCure and Design is -0.37. Overlapping area represents the amount of risk that can be diversified away by holding NextCure and Design Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Design Therapeutics and NextCure is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NextCure are associated (or correlated) with Design Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Design Therapeutics has no effect on the direction of NextCure i.e., NextCure and Design Therapeutics go up and down completely randomly.

Pair Corralation between NextCure and Design Therapeutics

Given the investment horizon of 90 days NextCure is expected to under-perform the Design Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, NextCure is 1.46 times less risky than Design Therapeutics. The stock trades about -0.18 of its potential returns per unit of risk. The Design Therapeutics is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  566.00  in Design Therapeutics on September 23, 2024 and sell it today you would earn a total of  59.00  from holding Design Therapeutics or generate 10.42% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

NextCure  vs.  Design Therapeutics

 Performance 
       Timeline  
NextCure 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days NextCure has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Design Therapeutics 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Design Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady technical and fundamental indicators, Design Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

NextCure and Design Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with NextCure and Design Therapeutics

The main advantage of trading using opposite NextCure and Design Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NextCure position performs unexpectedly, Design Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will offset losses from the drop in Design Therapeutics' long position.
The idea behind NextCure and Design Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Other Complementary Tools

Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets